Statins and the reduction of sudden cardiac death: Antiarrhythmic or anti-ischemic effect?

American Journal of Cardiovascular Drugs

Volumn 10, Issue 3, 2010, Pages 155-164

  Beri, Abhimanyu ^a   Contractor, Tahmeed ^a   Khasnis, Atul ^b   Thakur, Ranjan ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Thoracic and Cardiovascular Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; ROSUVASTATIN;

ACUTE HEART INFARCTION; ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIISCHEMIC EFFECT; AUTONOMIC NERVOUS SYSTEM; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; MODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; SYSTEMATIC REVIEW;

ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL ISCHEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 77953271895     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11536690-000000000-00000     Document Type: Review

References (87)

1. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: structure, function, and time-dependence of risk. Circulation 1992 Jan; 85 (1 Suppl.): I2-10
2. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation 2004 Jun 8; 109 (22): 2685-2691
3. Arshad A, Mandava A, Kamath G, et al. Sudden cardiac death and the role of medical therapy. Prog Cardiovasc Dis 2008 May-Jun; 50 (6): 420-438
4. Priori SG, Aliot E, Blømstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2006 Sep; 27 (17): 2099-2140
5. De Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Outof-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997 Nov 15; 30 (6): 1500-1505
6. Toyoshima H, Hayashi S, Tanabe N, et al. Sudden death of adults in Japan. Nagoya J Med Sci 1996 Dec; 59 (3-4): 81-95
7. Kawakubo K, Lee JS. Incidence rate of sudden death in Japan.Nippon Rinsho 2005 Jul; 63 (7): 1127-1134
8. Kostapanos MS, Liberopoulos EN, Goudevenos JA, et al. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007 Jul 1; 75 (1): 10-20
9. Bayé s de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989 Jan; 117 (1): 151-159
10. Huikuri HV, Castellanos GA, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001 Nov 15; 345 (20): 1473-1482
11. Myerburg RJ, Mitrani R, Interian Jr A, et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998 Apr 21; 97 (15): 1514-1521
12. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118
13. Vyas AK, Guo H, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006 Feb 21; 47 (4): 769-773
14. Mehta D, Curwin J, Gomes JA, et al. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation 1997 Nov 4; 96 (9): 3215-3223
15. Ducceschi V, Di Micco G, Sarubbi B, et al. Ionic mechanisms of ischemiarelated ventricular arrhythmias. Clin Cardiol 1996 Apr; 19 (4): 325-331
16. Antall BS, Naimi AH, Brilla AH, et al. A computerized system for measuring dispersion of repolarization in the intact heart. J Appl Physiol 1974 Sep; 37 (3): 456-458
17. Horacek T, NeumannM,Mutius S, et al. Nonhomogeneous epicardial changes and the bimodal distribution of early ventricular arrhythmias during acute coronary artery occlusion. Basic Res Cardiol 1984 Nov-Dec; 79 (6): 649-667
18. Meissner MD, Akhtar M, Lehmann MH. Nonischemic sudden tachyarrhythmic death in atherosclerotic heart disease. Circulation 1991 Aug; 84 (2): 905-912
19. Akhtar M. Clinical spectrum of ventricular tachycardia. Circulation 1990Nov; 82 (5): 1561-1573
20. Denniss AR, Richards DA, Waywood JA, et al. Electrophysiological and anatomic differences between canine hearts with inducible ventricular tachycardia and fibrillation associated with chronic myocardial infarction. Circ Res 1989 Jan; 64 (1): 155-166
21. DeBakker JMT, Van Capelle FJL, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988 Mar; 77 (3): 589-606
22. Gardner PI, Ursell PC, Fenoglio JJ, et al. Electrophysiologic and anatomic basis for fractionated electrograms recorded from healed myocardial infarcts. Circulation 1985 Sep; 72 (3): 596-611
23. De Sutter J, Firsovaite V, Tavernier R. Prevention of sudden death in patients with coronary artery disease: do lipid-lowering drugs play a role? Prev Cardiol 2002 Fall; 5 (4): 177-182
24. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998 Nov 24; 98 (21): 2334-2351
25. Wit AL, Janse MJ. Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction. Circulation 1992 Jan; 85 (1 Suppl.): I32-42
26. Martin GJ,Magid NM, Myers G, et al. Heart rate variability and sudden death secondary to coronary artery disease during ambulatory electrocardiographic monitoring. Am J Cardiol 1987 Jul 1; 60 (1): 86-89
27. Bigger JT, Fleiss JL, Steinman RC, et al. Correlations among time and frequency domain measures of heart period variability two weeks after acute myocardial infarction. Am J Cardiol 1992 Apr 1; 69 (9): 891-898
28. Schwartz PJ, LaRovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death: experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992 Jan; 85 (1 Suppl.): I77-91
29. Kleiger RE, Miller JP, Bigger Jr JT, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987 Feb 1; 59 (4): 256-262
30. Kliks BR, Burgess MJ, Abildskov JA. Influence of sympathetic tone on ventricular fibrillation threshold during experimental coronary occlusion. Am J Cardiol 1975 Jul; 36 (1): 45-49
31. Zipes DP. Sympathetic stimulation and arrhythmias. N Engl J Med 1991 Aug 29; 325 (9): 656-657
32. Majmudar MD, Tompkins C, Bachmann JM, et al. Effects of lipid-altering therapies on ventricular arrhythmias and sudden cardiac death. Cardiol Rev 2009 Mar-Apr; 17 (2): 60-69
33. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 Nov 29; 345 (22): 1583-1592
34. Levantesi G, Scarano M, Marfisi R, et al. Meta-analysis of effect of statin treatment on risk of sudden death.AmJCardiol 2007 Dec 1; 100 (11): 1644-1650
35. Haerem JW. Mural platelet microthrombi and major acute lesions of main epicardial arteries in sudden coronary death. Atherosclerosis 1974 May-Jun; 19 (3): 529-541
36. Haerem JW. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease. Atherosclerosis 1972 Mar-Apr; 15 (2): 199-213
37. Davies MJ, Thomas AC, Knapman PA, et al. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986 Mar; 73 (3): 418-427
38. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 1985 Apr; 71 (4): 699-708
39. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005 Feb; 25 (2): 287-294
40. Tousoulis D, Bosinakou E, Kotsopoulou M, et al. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol 2006 Jan 26; 106 (3): 333-337
41. Tekten T, Ceyhan C, Ercan E, et al. The effect of atorvastatin on platelet function in patients with coronary artery disease. Acta Cardiol 2004 Jun; 59 (3): 311-315
42. Pirro M, Schillaci G, Romagno PF, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. JCardiovasc Pharmacol Ther 2009 Mar; 14 (1): 14-21
43. REGRESS Study Group, van Boven AJ. Pravastatin but not placebo reduces heart rate variability after 2 years in patients with stable angina pectoris [abstract]. Circulation 1995; 92: 145
44. Riahi S, Christensen JH, Toft E, et al.HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol Res 2002 Jun; 45 (6): 479-483
45. Pehlivanidis AN, Athyros VG, Demitriadis DS, et al. Heart rate variability after long term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157: 463-469
46. Welzig CM, Shin DG, Park HJ, et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2),a possible molecular marker for parasympathetic responsiveness. Circulation 2003 Dec 2; 108 (22): 2743-2746
47. Riahi S, Schmidt EB, Amanavicius N, et al. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. Int J Cardiol 2006 Aug 28; 111 (3): 436-441
48. Gentlesk PJ, Wiley T, Taylor AJ. A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am Heart J 2005 Sep; 150 (3): 478-483
49. Mallavarapu C, Pancholy S, Schwartzman D, et al. Circadian variation of ventricular arrhythmia recurrence after cardioverter-defibrillator implantation in patients with healed myocardial infarcts. Am J Cardiol 1995 Jun 1; 75 (16): 1140-1144
50. d'Avila A, Wellens F, Andries E, et al. At what time are implantable defibrillator shocks delivered? Evidence for individual circadian variance in sudden cardiac death. Eur Heart J 1995 Sep; 16 (9): 1231-1233
51. Chu CS, Lee KT, Lee ST, et al. Effects of atorvastatin on ventricular late potentials and repolarization dispersion in patients with hypercholesterolemia. Kaohsiung J Med Sci 2007 May; 23 (5): 217-224
52. Opper C,Weiner N, Xü F, et al. Daily variations of functional parameters and density distribution in human blood platelets. Chronobiol Int 1994 Oct; 11 (5): 309-319
53. Kayikcioglu M, Can L, Evrengul H, et al. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 2003 Jul; 90 (1): 63-72
54. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005 Sep 1; 96 (5): 611-616
55. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction. Arch Intern Med 2004 Oct 25; 164 (19): 2162-2168
56. Dewey FE, Perez M, Hadley D, et al. Statin use and ventricular arrhythmias during clinical treadmill testing. J Cardiovasc Electrophysiol 2009 Feb; 20 (2): 193-199
57. Dewey FE, Kapoor JR, Williams RS, et al. Ventricular arrhythmias during clinical treadmill testing and prognosis. Arch Intern Med 2008 Jan 28; 168 (2): 225-234
58. Maguy A, Hebert TE, Nattel S. Involvement of lipid rafts and caveolae in cardiac ion channel function. Cardiovasc Res 2006 Mar 1; 69 (4): 798-807
59. Liu YB, Lee YT, Pak HN, et al. Effects of simvastatin on cardiac neural and electrophysiologic remodeling in rabbits with hypercholesterolemia. Heart Rhythm 2009 Jan; 6 (1): 69-75
60. Ding C, Fu XH, He ZS, et al. Cardioprotective effects of simvastatin on reversing electrical remodeling induced by myocardial ischemia-reperfusion in normocholesterolemic rabbits. Chin Med J (Engl) 2008 Mar 20; 121 (6): 551-556
61. Henry PD, Pacifico A. Altering molecular mechanisms to prevent sudden arrhythmic death. Lancet 1998 Apr 25; 351 (9111): 1276-1278
62. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001 Apr 3; 103 (13): 1813-1818
63. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997 Apr 3; 336 (14): 973-979
64. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000 Mar 23; 342 (12): 836-843
65. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 Nov 20; 359 (21): 2195-2207
66. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE). A randomized trial and cohort study. JAMA 2001 Jul 4; 286 (1): 64-70
67. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 Jun 4; 105 (22): 2595-2599
68. Abuissa H, O'Keefe JH, Bybee KA. Statins as anti-arrhythmics: a systematic review. Part II: effects on risk of ventricular arrhythmias. Clin Cardiol 2009 Oct; 32 (10): 549-552
69. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994 Nov 19; 344 (8934): 1383-1389
70. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS. JAMA 1998 May 27; 279 (20): 1615-1622
71. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339 (19): 1349-1357
72. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346
73. Hognestad A, Dickstein K, Myhre E, et al. Effect of combined statin and betablocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 2004Mar 1; 93 (5): 603-606
74. Mäkikallio TH, Barthel P, Schneider R, et al. Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. Am J Cardiol 2006 Feb 15; 97 (4): 480-484
75. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007 Nov 29; 357 (22): 2248-2261
76. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008 Mar; 14 (2): 140-144
77. GISSI-HF Investigators, Tavazzi L,Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 Oct 4; 372 (9645): 1231-1239
78. De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000; 36: 766-772
79. Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003 Jul 2; 42 (1): 81-87
80. Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator.AmJCardiol 2005 Feb 15; 95 (4): 490-491
81. Riahi S, Schmidt EB, Christensen JH, et al. Statins, ventricular arrhythmias and heart rate variability in patients with implantable cardioverter defibrillators and coronary heart disease. Cardiology 2005; 104 (4): 210-214 (Pubitemid 41407277)
82. De Sutter J, De Bacquer D, Jordaens L, et al. Intensive lipid-lowering therapy and ventricular arrhythmias in patients with coronary artery disease and internal cardioverter defibrillator implants: the CLARIDI trial [abstract]. Heart Rhythm 2006 Sep; 3 (9): 1126
83. Goldberger JJ, Subacius H, Schaechter A, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2006 Sep 19; 48 (6): 1228-1233
84. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure trial (SCD-HeFT). Am Heart J 2007 Apr; 153 (4): 573-578
85. Coleman CI, Kluger J, Bhavnani S, et al. Association between statin use and mortality in patients with implantable cardioverter defibrillators and left ventricular systolic dysfunction. Heart Rhythm 2008 Apr; 5 (4): 507-510
86. McMurray JJV, Kjekshus J, Gullestad L, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009 Dec 1; 120 (22): 2188-2196
87. Guo HM. Anti-arrhythmic effects of statins: a hypothesis remains to be tested. Heart Rhythm 2008 Apr; 5 (4): 511-512